Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Bortezomib; Dexamethasone; Pasireotide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned End Date changed from 1 Apr 2016 to 1 Dec 2014 as reported by ClinicalTrials.gov.